产品详情
简单介绍:
重组鼠白细胞介素-33蛋白与其它公司提供的重组蛋白不同,rMuIL-33蛋白产品为采用CFS的无细胞麦胚蛋白合成系统表达出来的重组蛋白,可表达出对细胞有毒性、易被蛋白酶降解的蛋白;并获得具有良好的可溶性,并有翻译后修饰、从而部分具有功能的蛋白.同时独有的全自动蛋白纯化技术则简便高效,将蛋白纯化过程中对蛋白的损伤降低到*小程度.重组鼠白细胞介素-33蛋白(全长序列)产品可用于Western Blot验证、抗体制备、蛋白检测、ELISA等试验中.
详情介绍:
重组鼠白细胞介素-33蛋白
Synonyms | IL-1F11, NF-HEV |
Species | Murine |
Accession | Q8BVZ5 |
GeneID | 77125 |
Source | Escherichia coli. |
Molecular Weight | 重组鼠白细胞介素-33蛋白Approximately 17.5 kDa protein containing 158 amino acid residues. |
Quantity | 2µg/10µg/1000µg |
AA Sequence | SIQGTSLLTQ SPASLSTYND QSVSFVLENG CYVINVDDSG KDQEQDQVLL RYYESPCPAS QSGDGVDGKK LMVNMSPIKD TDIWLHANDK DYSVELQRGD VSPPEQAFFV LHKKSSDFVS FECKNLPGTY IGVKDNQLAL VEEKDESCNN IMFKLSKI |
Purity | > 98 % by SDS-PAGE and HPLC analyses. |
Biological Activity | 重组鼠白细胞介素-33蛋白Fully biologically active when compared to standard. The ED50as determined by a cell proliferation assay using murine D10S cells is less than 0.5 ng/ml, corresponding to a specific activity of > 2.0 × 106IU/mg. |
Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
Formulation | Lyophilized from a 0.2 µm filtered solution in PBS, and 1 mM EDTA. |
Endotoxin | Less than 1 EU/µg of rMuIL-33 as determined by LAL method. |
Reconstitution | 重组鼠白细胞介素-33蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
重组鼠白细胞介素-33蛋白 | |
SDS-PAGE | |
Reference | 1. Arend WP, Palmer G, Gabay C. 2008. Immunol Rev, 223: 20-38. 2. Ajdukovic J, Tonkic A, Salamunic I, et al. 2010. Hepatogastroenterology, 57: 1442-4. 3. Ho LH, Ohno T, Oboki K, et al. 2007. J Leukoc Biol, 82: 1481-90. 4. Miller AM, Xu D, Asquith DL, et al. 2008. J Exp Med, 205: 339-46. 5. Blom L, Poulsen BC, Jensen BM, et al. 2011. PLoS One, 6: e21695. |
Background | IL-33 is a number of IL-1 superfamily, secreted by high endothelial venules at high levels, which is found in tonsils, peyer patches and mesenteric lymph nodes, but not in placenta. It elicits its biological effects by interacting with IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. IL-33 induces production of TH2 cell related cytokines, including IL-4, IL-5 and IL-13, and exerts multiple inflammation related bioactivities. Mature IL-33 share approximately 55 % and 90 % a.a. sequence identity with human and rat IL-33 respectively. |